Replies to post #193725 on Biotech Values

[DewDiligence]

Re: AMGN’s threat from FoBs

http://www.wsj.com/articles/amgen-to-undergo-experimental-treatment-1438363128

At about 18 times forward earnings, Amgen stock isn’t especially pricey for a large biotech. But…for Amgen to maintain or grow its valuation, biosimilars need to arrive with a whimper, not a roar.

In 2Q15, 36% of AMGN’s product sales came from Epogen, Neupogen, and Neulasta, which are off-patent in the US and several other major countries.

[DewDiligence]

SRNE licenses 4 FoB programs from China’s Mabtech:

http://finance.yahoo.com/news/sorrento-licenses-four-stage-clinical-100000760.html

Under the terms of the agreement, Sorrento will develop and market these 4 monoclonal antibodies (mAbs) for the North American, European and Japanese market.

Each of the mAbs has completed a Phase III study; two are currently in registration for marketing approval in China, while the other two are under data analyses for subsequent NDA submission in China. One of the biobetter mAbs is based on a Top 10-selling oncology drug and the other a Top 5-selling antibody to treat auto-immune diseases.

Financial terms and the identities of the four programs have not been disclosed.

[DewDiligence]

Announced FoB Collaborations

[Updates re AMGN-AGN collaboration.]


Items are shown in reverse chronological order. This table does not purport to be exhaustive.

 
                     Date   Targets   Geography     iHub References 
 AZN-Fujifilm/Kyowa  7/15   Avastin   global        #msg-115666552 
 PFE(HSP)-PFNX       2/15   Lucentis  global        #msg-110725481 
 Merck KGaA-Hanwha   2/15   Enbrel    ex-US         #msg-110668714 
 EPRS-Livzon         9/14   5 mAbs    China         #msg-106600322 
 NeuClone-Serum Inst 7/14   10 mAbs   global        #msg-104136710 
 Liomont-Oncobiolgcs 6/14   2 mAbs    Mexico        #msg-103754486 
 PlantForm-PhrmaPrxs 6/14   Avastin   Brazil        #msg-103576633 
 Lupin-Yoshindo      4/14   Enbrel    Japan         #msg-101018361 
 EPRS-Ranbaxy        1/14   Remicade  Asia/Africa   #msg-95745192 
 BXLT-CHRS           9/13   Enbrel    ex-US         #msg-91645674 
 Oncobiolgcs-Huahai  5/13   #         global        #msg-87734336,#msg-87744882 
 Strides-Pfenex      4/13   Betaseron global        #msg-87014470 
 MRK-Samsng/BIIB     2/13   @         @             #msg-114478003,#msg-84781042,#msg-69629103 
 Catalent-UMN       12/12   various   Asia          #msg-82556713 
 Merck KGaA-RDY      6/12   oncology  global        #msg-76359649 
 Daiichi-CHRS        5/12   Enbrel    Asia          #msg-75397629 
 Fujifilm-Kyowa      3/12   Humira    unspecified   #msg-73800486 
 AGN-Bioton          2/12   insulin   US & Europe   #msg-74987123 
 AGN-AMGN           12/11   †         global        #msg-70097496,#msg-117190738 
 BXLT-MNTA          12/11   Humira    global        #msg-110925786 
 PFE(HSP)-Celltrion 10/09   z         global        #msg-84519981,#msg-77816122 
 MYL-Biocon          6/09   x         global        #msg-72421544,#msg-84561737 
 Procognia-UTR       n/a    Humira    unspecified   #msg-84340976 

†Herceptin, Avastin, Rituxan, Erbitux; AMGN working independently on Humira and Remicade.

@ Enbrel [worldwide except US/EU/Japan], Remicade [worldwide except EU/Russia/Turkey], Humira [worldwide except EU/Russia/Turkey], Herceptin [worldwide], Lantus [worldwide].

#Humira, Rituxan, Avastin, Herceptin.

x Nine products: Herceptin, Neulasta, Avastin, Humira, Enbrel, Lantus, Novolog, Humalog, one undisclosed.

z Each company received a distinct EU/CHMP approval for Remicade on 6/28/13; partnership includes seven (other) products: Rituxan, Herceptin, Enbrel, Erbitux, Synagis, Humira, Avastin.